Figure 2From: Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scidmiceEffect of gemcitabine and rituximab on cell cycle. Cells (0.25 × 106/ml) incubated ± 20 μg/ml rituximab for 4 hr, then ± 2.5 nM gemcitabine for 24 hr. Cells stained with propidium iodide, analyzed by flow and cell cycle parameters calculated (ModFit LT program). A typical flow result is also shown (Figure 2A).Back to article page